2019-10-22 09:50:161970-01-01 00:00:00

Blackmores to Profit off Flu Season

A seasonal pick-up of consumers purchasing vitamin-C tablets and other health supplements is providing a revenue bump for Blackmores (ASX: BKL). However, this is not likely to trigger a price surge like that of 2014-2015 on the back of extraordinary demand from China.

Since the company’s value declined from a peak of $220 in 2014-2015 to inbetween $90 and $100 currently, Blackmores’ slump has mainly been attributed to a slowdown of sales to China. This decrease is said to be due to onsellers on e-commerce sites and the company grappling with a vacuum at the top of its executive ranks.

Looking at their most recent third-quarter analysts briefing, the company notes revenue decreased 4% compared to the previous corresponding period. This was attributed to softening sales in the quarter due to a deliberate move to clear inventory channels in China and a non-repeat of promotional activity from the previous corresponding period. China segment sales are up 19% which were estimated to decline by ~6%, impacted upon by slowing sales through Australian retailers.

The overall story in Asia is positive with Hong Kong up 18%, Taiwan increasing 81%, while Korea and Indonesia increased 13% and 99% respectively. While profit has fallen this quarter to $10 million, with operating expenses lower by 1%,  Blackmores proudly announced its continued market dominance of almost 15% market share domestically.

Morgan Stanley analyst Tom Kierath is still cautious on Blackmore, but has lifted his 12-month price target on the stock from $75 to $84 – he expects Blackmores to report a net profit after tax of $64 million. Credit Suisse also shares a similar position and has a “neutral” rating and a 12-month price target of $85. This has led the stock to experience a period of volatility last week, with shares surging 6.14% on May 30th, only to fall 4.46% the following day.

Forecasts predict that this year’s flu season is expected to be one of the worst seasons Australia has experienced in decades. Local health authorities say the flu season has started earlier than expected, which is likely why first quarter sales in 2019-2020 are expected to rise on the back of the macro-trend. Laboratory-confirmed flu cases are “well ahead of any of the previous five years at this early stage in the season” Mr Kierath said in the Australian Influenza Surveillance Report.

Another indicator that sales are spiking is Google search data in Australia for keywords including “flu”, “cold and flu”, “vitamin C” and for Chemist Warehouse – the largest domestic retailer for Blackmores supplements and competitors such as Swisse. Mr Kierath said he expects this information to translate into strong sales figures heading into the June-quarter and September-quarter sales, after a 26% decline as the domestic retail channel was cleared.

Blackmores’ main rival domestically – Swisse – which was purchased for $1.7 billion by Hong Kong-listed  Health & Happiness in late 2015 and 2016 in a two-tranche acquisition also experienced some hard-ship as ‘daigou’ traders backed off purchasing Australian supplements.

Swisse sales reportedly dropped 25.2% for the three months ended March 31, according to Health & Happiness chairman Luo Fei. However, Chinese sales increased 32.2%.

“The sales drop in the Australian market was due to new China e-commerce regulations that started from January 1, 2019, as a result of which some daigou’s have de-stocked inventory and reduced trading,” Mr Fei said. The ‘daigou’ traders – who purchase large volumes of vitamins and mineral supplements from Australian retailers and sell them on e-commerce sites in China – were a predominant force that drove Blackmores sales higher towards the end of 2014 calendar year.

The company also has been reviewing efficiency and productivity levels. Highlighting a notable increase to staffing in 2015-2016 and 2017-2018 saw numbers increase 18% (over 1400 employees) all while sales were largely flat. As a result, net sales per employee fell 15% and if Blackmores were to return to 2015-2016 staffing level, it would imply $27 million in cost savings. Marcus Blackmore concedes that the company became too bloated and needed to return to being “lean and mean” – which likely means layoffs.

Blackmores’ can expect to receive a seasonal domestic spike in supplement sales, off the back of anxious consumers concerned about the eminent flu season. The season is expected to be harsher than most with health authorities warning it could be the worst in decades, this coincides with pharmacies and general practitioners in NSW running out of influenza vaccines.

By Sydney  Robertson

Click here for a 7 days access to our Lotus Blue Portal.

KOSEC does not take into account the investment objectives, financial situation and advisory needs of any particular person, nor does the information provided constitute investment advice. Under no circumstances should investments be based solely on the information provided. KOSEC is intended to provide general information only. Please be aware that investing involves the risk of capital loss. This message is confidential and may be privileged. It is intended only for the use of the addressee named above. If you are not the intended recipient, any unauthorised dissemination, distribution or copying is illegal. We do not guarantee the security or completeness of information hereby transmitted and are not liable in either respect or in respect of any delay. Nothing in this message is intended as an offer or solicitation for the purchase or sale of any financial instrument. Any market prices or data, unless specifically verified and identified as such, are not warranted as to completeness or accuracy. Kodari Securities Pty Ltd (KOSEC) is a Corporate Authorised Representative (No. 399 556) of Longhou Capital Markets (AFSL No. 292464) which is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC wishes to disclose that KOSEC and its staff may hold stock they recommend in their own portfolios and that any decision to purchase recommended stock should be done so after the purchaser has made their own inquires as to the suitability to their own requirements. Click here to view our FSG.

KOSEC Terms & Conditions

Kodari Securities Pty Ltd (CAR 399556) trading as KOSEC is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC is a financial services company and any information provided by its platforms, portals, reports and documents is protected by copyright. Any unauthorised production of this information is prohibited.
KOSEC reserves the right to change or remove any information provided on our website, reports or any documents including these terms and conditions at any time without notice. The change or modification to the terms and conditions will be effective immediately upon posting an updated version on our website, necessary platforms and documents. It is recommended that you review the information provided on our website, including these terms and conditions frequently for any changes.

KOSEC provides general advice only. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. KOSEC recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Please make sure you read our Financial Services Guide (FSG).

KOSEC does not guarantee any returns. Past performance of any product discussed is not indicative of future performance. (We urge that caution should be exercised in assessing past performance. All financial products are subject to market forces and unpredictable events that may adversely affect their future performance). Investing in the stock market can incur huge losses. Please also be aware that fees will incur on every transaction regardless of the performance of your investments or returns generated. Employees and or associates of KOSEC may hold one or more of the stocks, securities or investments reviewed by the company.

Your use of information from our website, reports, documents and from talking to our representatives/associates is at your risk. Under no circumstance should the investment be based solely on KOSEC information and general advice. You should seek professional financial planning advice.
KOSEC aims to maintain the accuracy of the data and information provided on this website, by using information prepared from a wide variety of sources, which KOSEC to the best of its knowledge and belief, considers accurate and does not make any representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability of the information provided.

We may at times refer to third parties, which the details of these third parties have been provided solely for you to obtain further information about other relevant products and entities in the market. KOSEC has no control over the information third parties have, or the products or services offered, and therefore make no representations regarding the accuracy or suitability of such information, products or services. You are advised to make your own enquiries in relation to third parties. Our inclusion of any third party content is not an endorsement of that content or the third party.

As a client you will be charged a yearly service fee and a set brokerage fee per transaction. Your service fee will automatically renew at the end of your agreed 12 month period at the same rate advertised at the time. Your credit card or bank account will be charged for a further year following which will again auto renew until you cancel your yearly service fee. You can cancel the auto renewal at any time in advance of the renewal date by contacting us. KOSEC is aware of the need to ensure the security of your credit card details and our payment systems are compliant with the Payment Card Industry (PCI) Data Security Standard.

You consent to receiving email correspondence from KOSEC, as well as companies KOSEC has an association with. These emails will be sent by KOSEC and third party companies. You can opt out of receiving any category of emails at any time by contacting us. We may from time to time inform you of special offers, or even ask your opinion of the services we provide, but your involvement is optional. Should you request us to do so, we will archive your details.

Indemnity and Liability
You indemnify KOSEC from all claims or threatened claims, suits, demands, damages, costs as well as including legal costs incurred in dealing with any threatened claim, expenses made by any person or corporation against KOSEC and any other amounts which is caused by KOSEC providing information, execution and General Advice.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from a decision made by you on the basis of information obtained through the use of our portal, reports, documents or any General Advice given and any transaction taken place.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from delays in executing orders for the client and acknowledges KOSEC makes no guarantees about the time taken to execute an order on behalf of the client. You acknowledge that KOSEC relies on third parties in providing technology and release KOSEC from any harm, loss or damage you may suffer as a result of the failure of such information technology.

Cookies and Links
KOSEC website, and its portal uses cookies, which lets us identify your browser while you are using the site or our portal. Cookies do not identify you personally. They simply allow us to track your usage patterns. If you prefer not to receive cookies, you can configure your browser to reject them or to notify you when they are being used. The functionality of the KOSEC website may be impacted if you restrict the use of cookies.

Fill up the form below and we will get back to you as soon as possible.



KOSEC’s CEO, Michael Kodari’s new book, “Stock Market Success” valued at $39.95, available at Dymocks book stores with all the proceeds going to Dymocks Children’s Charities.


Latest TV Commercial